맞춤형 의료 시장 : 예측(2026-2031년)

Personalized Medicine Market, with a 8.76% CAGR, is anticipated to reach USD 767.383 billion in 2031 from USD 463.680 billion in 2025.

The personalized medicine market represents a fundamental shift in healthcare, moving away from a one-size-fits-all model towards a targeted, data-driven approach to diagnosis, treatment, and prevention. This paradigm tailors medical decisions and interventions to the individual characteristics of each patient, integrating genetic, molecular, environmental, and lifestyle information. Enabled by converging technological advancements, the market is revolutionizing therapeutic areas from oncology to cardiology by improving treatment efficacy, minimizing adverse events, and optimizing healthcare resource utilization. Its growth is propelled by breakthroughs in genomic science, the expansion of diagnostic capabilities, and strategic realignments across the pharmaceutical and diagnostic industries.

The core technological driver of this market is the continuous advancement in genomics and multi-omics technologies. The precipitous decline in the cost and time of genomic sequencing, coupled with the maturation of proteomics, metabolomics, and transcriptomics, has unlocked unprecedented ability to characterize an individual's molecular profile. This deep biological insight allows for the identification of specific biomarkers-genetic mutations, protein expressions, or metabolic signatures-that can predict disease susceptibility, prognosis, and response to therapy. The ability to stratify patients based on these molecular drivers is the foundational principle of personalized medicine, enabling the development and application of targeted therapeutics and diagnostics.

A critical application driving clinical adoption is the growth of pharmacogenomics-the study of how an individual's genetic makeup affects their response to drugs. By identifying genetic variants that influence drug metabolism, efficacy, and toxicity, clinicians can optimize medication selection and dosing before treatment begins. This approach demonstrably reduces the trial-and-error process in prescribing, decreases the incidence of adverse drug reactions, and improves therapeutic outcomes. As evidence of its clinical utility and cost-effectiveness accumulates, pharmacogenomics is becoming increasingly integrated into standard care pathways and drug development processes, solidifying its role within the personalized medicine ecosystem.

Parallel to therapeutic advances is the expansion and sophistication of personalized diagnostics and companion diagnostics. The market is moving beyond single-gene tests to complex multi-analyte assays and next-generation sequencing panels that can interrogate hundreds of genomic targets simultaneously. Companion diagnostics, which are tests specifically linked to the use of a corresponding therapeutic product, are now a regulatory and commercial prerequisite for many targeted cancer therapies. The development of these diagnostics is essential for identifying the patient subpopulation most likely to benefit from a specific drug, thereby ensuring treatment is delivered to the right patient, maximizing clinical benefit and supporting the value proposition of high-cost specialty pharmaceuticals.

The competitive and collaborative landscape is a defining feature of the market. Success in personalized medicine requires deep integration across traditionally separate domains. This has led to a surge in strategic collaborations and partnerships between pharmaceutical companies, diagnostic developers, technology/platform providers, and data analytics firms. Pharmaceutical companies leverage these alliances to embed biomarker strategies early in drug development, while diagnostic companies gain access to therapeutic pipelines and clinical validation pathways. These synergies are accelerating the translation of research into clinically actionable tools and treatments, reducing development timelines and improving the probability of regulatory and commercial success.

Geographically, North America maintains a leading position, driven by a confluence of factors. These include a robust biotechnology and pharmaceutical sector, substantial public and private investment in genomic research, a relatively favorable regulatory environment for novel diagnostics and targeted therapies, and high healthcare expenditure that can support advanced testing. The region's well-established infrastructure for clinical trials and a growing emphasis on value-based care models that reward improved outcomes further reinforce its role as the primary incubator and early adopter of personalized medicine innovations.

The market encompasses a broad value chain, from the technology platforms enabling analysis-such as next-generation sequencers and high-throughput instrumentation-to the diagnostic test developers, bioinformatics companies interpreting complex data, and the therapeutic developers creating matched targeted drugs. Key industry players often compete and collaborate across multiple points in this chain, with leaders in sequencing technology providing the essential tools that enable the entire field.

In conclusion, the personalized medicine market is transitioning from a promising concept to a central organizing principle of modern biomedical research and clinical care. Its growth trajectory is inextricably linked to the ongoing expansion of biological knowledge, computational power, and data integration capabilities. Future development will be shaped by challenges including the standardization of testing, the establishment of clear reimbursement pathways for complex diagnostics, the need for clinician education, and the ethical management of genetic data. However, the demonstrated ability to improve patient outcomes and the economic imperative to direct costly therapies more efficiently ensure that personalized medicine will continue to redefine standards of care across a growing spectrum of diseases, making healthcare more predictive, preventive, and precise.

Key Benefits of this Report:

• Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
• Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
• Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
• Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
• Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

• Historical data from 2021 to 2025 & forecast data from 2026 to 2031
• Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
• Competitive Positioning, Strategies, and Market Share Analysis
• Revenue Growth and Forecast Assessment of segments and regions including countries
• Company Profiling (Strategies, Products, Financial Information, and Key Developments among others.)

Personalized Medicine Market Segmentation

• By Type
• Pharmacogenomics
• Biomarkers
• Precision Therapeutics
• Others
• By Application
• Oncology
• Cardiology
• Infectious Disease
• Neurology
• Others
• By End-User
• Hospitals & Clinics
• Diagnostics Centers
• Others
• By Geography
• North America
• USA
• Canada
• Mexico
• South America
• Brazil
• Argentina
• Others
• Europe
• Germany
• France
• United Kingdom
• Spain
• Italy
• Others
• Middle East and Africa
• Saudi Arabia
• UAE
• Others
• Asia Pacific
• China
• India
• Japan
• South Korea
• Indonesia
• Thailand
• Taiwan
• Others

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

• 2.1. Market Overview
• 2.2. Market Definition
• 2.3. Scope of the Study
• 2.4. Market Segmentation

3. BUSINESS LANDSCAPE

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Porter's Five Forces Analysis
• 3.5. Industry Value Chain Analysis
• 3.6. Policies and Regulations
• 3.7. Strategic Recommendations
• 3.8. Products in Pipeline

4. TECHNOLOGICAL OUTLOOK

5. PERSONALIZED MEDICINE MARKET BY TYPE

• 5.1. Introduction
• 5.2. Pharmacogenomics
• 5.3. Biomarkers
• 5.4. Precision Therapeutics
• 5.5. Others

6. PERSONALIZED MEDICINE MARKET BY APPLICATION

• 6.1. Introduction
• 6.2. Oncology
• 6.3. Cardiology
• 6.4. Infectious Disease
• 6.5. Neurology
• 6.6. Others

7. PERSONALIZED MEDICINE MARKET BY END-USER

• 7.1. Introduction
• 7.2. Hospitals & Clinics
• 7.3. Diagnostics Centers
• 7.4. Others

8. PERSONALIZED MEDICINE MARKET BY GEOGRAPHY

• 8.1. Introduction
• 8.2. North America
  • 8.2.1. By Type
  • 8.2.2. By Application
  • 8.2.3. By End-User
  • 8.2.4. By Country
    • 8.2.4.1. USA
    • 8.2.4.2. Canada
    • 8.2.4.3. Mexico
• 8.3. South America
  • 8.3.1. By Type
  • 8.3.2. By Application
  • 8.3.3. By End-User
  • 8.3.4. By Country
    • 8.3.4.1. Brazil
    • 8.3.4.2. Argentina
    • 8.3.4.3. Others
• 8.4. Europe
  • 8.4.1. By Type
  • 8.4.2. By Application
  • 8.4.3. By End-User
  • 8.4.4. By Country
    • 8.4.4.1. Germany
    • 8.4.4.2. France
    • 8.4.4.3. United Kingdom
    • 8.4.4.4. Spain
    • 8.4.4.5. Italy
    • 8.4.4.6. Others
• 8.5. Middle East and Africa
  • 8.5.1. By Type
  • 8.5.2. By Application
  • 8.5.3. By End-User
  • 8.5.4. By Country
    • 8.5.4.1. Saudi Arabia
    • 8.5.4.2. UAE
    • 8.5.4.3. Others
• 8.6. Asia Pacific
  • 8.6.1. By Type
  • 8.6.2. By Application
  • 8.6.3. By End-User
  • 8.6.4. By Country
    • 8.6.4.1. China
    • 8.6.4.2. India
    • 8.6.4.3. Japan
    • 8.6.4.4. South Korea
    • 8.6.4.5. Indonesia
    • 8.6.4.6. Thailand
    • 8.6.4.7. Taiwan
    • 8.6.4.8. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

• 9.1. Major Players and Strategy Analysis
• 9.2. Market Share Analysis
• 9.3. Mergers, Acquisitions, Agreements, and Collaborations
• 9.4. Competitive Dashboard

10. COMPANY PROFILES

• 10.1. F. Hoffmann-La Roche Ltd.
• 10.2. Illumina, Inc.
• 10.3. Novartis Ag
• 10.4. Pfizer Inc.
• 10.5. Merck KgaA
• 10.6. Astrazeneca Plc
• 10.7. Bristol Myers Squibb Company
• 10.8. Amgen Inc.
• 10.9. Guardant Health Inc
• 10.10. Caris Life Sciences
• 10.11. Thermo Fisher Scientific Inc.

11. APPENDIX

• 11.1. Currency
• 11.2. Assumptions
• 11.3. Base and Forecast Years Timeline
• 11.4. Key Benefits for the Stakeholders
• 11.5. Research Methodology
• 11.6. Abbreviations